Stockreport

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term  CAMBRI [Read more]